HealthTech Focus Accelmed is a specialized lower middle-market private equity firm concentrating on acquiring and scaling commercial-stage HealthTech companies, presenting ongoing opportunities to engage portfolio companies in needs assessments for growth capital, operational optimization, and strategic exits.

Recent Acquisitions Active deal activity includes acquiring Bioness from Bioventus and investments in GT Medical Technologies, signaling a propensity for integrating adjacent HealthTech platforms and cross-sell or upsell through portfolio synergies and expanded product offerings.

Funding Capacity With over $630 million managed across funds and a current investment in Accelmed Partners II, there is substantial capacity to consider larger follow-on rounds, co-investments, or vendor financing opportunities to support portfolio growth.

Digital Presence Tech stack indicates active use of modern recruitment and SEO tools as well as cloud hosting, suggesting opportunities to offer digital transformation, talent acquisition enhancements, and robust marketing tech integrations to accelerate portfolio companies’ market reach.

Strategic Partnerships Distinct exits and asset sales to industry players (e.g., Bausch Health, Bioventus) imply openness to strategic collaborations, channel partnerships, and potential M&A scouting services to align with Accelmed’s portfolio exit strategies.